North Star Asset Management Inc. lifted its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 7.0% during the fourth quarter, Holdings Channel reports. The fund owned 14,602 shares of the biopharmaceutical company’s stock after acquiring an additional 950 shares during the period. North Star Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $895,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Delphi Private Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth about $108,000. Massey Quick Simon & CO. LLC lifted its holdings in shares of Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares during the period. Horan Capital Advisors LLC. acquired a new stake in shares of Bristol-Myers Squibb during the third quarter worth about $122,000. Atlantic Trust LLC acquired a new stake in shares of Bristol-Myers Squibb during the second quarter worth about $111,000. Finally, AllSquare Wealth Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the third quarter worth about $134,000. Institutional investors and hedge funds own 70.57% of the company’s stock.

Get Bristol-Myers Squibb alerts:

Bristol-Myers Squibb Co (NYSE BMY) opened at $66.17 on Monday. Bristol-Myers Squibb Co has a twelve month low of $51.56 and a twelve month high of $70.05. The stock has a market capitalization of $108,028.02, a P/E ratio of 21.98, a price-to-earnings-growth ratio of 2.06 and a beta of 0.98. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same period in the previous year, the company posted $0.63 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 3.9% on a year-over-year basis. equities research analysts predict that Bristol-Myers Squibb Co will post 3.21 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.42%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s payout ratio is 271.19%.

A number of equities research analysts recently commented on BMY shares. Citigroup set a $72.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Tuesday, December 5th. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Monday, December 11th. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 target price for the company. in a report on Friday, December 22nd. Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, Credit Suisse Group set a $62.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $66.18.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 4,000 shares of Bristol-Myers Squibb stock in a transaction dated Friday, December 15th. The stock was acquired at an average cost of $62.30 per share, with a total value of $249,200.00. Following the purchase, the director now directly owns 22,000 shares in the company, valued at approximately $1,370,600. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the transaction, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at $585,033.24. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb Co (BMY) Shares Bought by North Star Asset Management Inc.” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.watchlistnews.com/bristol-myers-squibb-co-bmy-shares-bought-by-north-star-asset-management-inc/1908791.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).